Cancer Research UK logo.
SearchDonate
  • Search

A trial of azacitidine and ruxolitinib for blood disorders called myeloproliferative neoplasms (PHAZAR)

Overview

Cancer types:

Blood cancers, Myelofibrosis, Polycythaemia, Thrombocythaemia

Status:

Closed

Phase:

Phase 1

Details

This trial is for people with advanced myeloproliferative neoplasms that include thrombocythaemia, polycythaemia vera or myelofibrosis.

Recruitment start: 5 January 2016

Recruitment end: 30 April 2019

How to join

Please note: In order to you will need to discuss it with your doctor, unless otherwise specified.

Chief investigators

Dr Mark Drummond

Supported by

Bloodwise

Celgene

Novartis

University of Birmingham

Last reviewed: 29 Apr 2019

CRUK internal database number: 12130

Help and support